India’s cheap weight-loss drugs coming to a pharmacy near you - What in the World, BBC World Service

Key Concepts

• GLP-1 (Glucagon-like peptide-1): A hormone that signals satiety to the brain; synthetic versions are used to treat obesity and type 2 diabetes.
• Semaglutide: The active pharmaceutical molecule in drugs like Wegovy and Ozempic.
• Generics: Medications produced after a patent expires, sold at a significantly lower cost because the manufacturer did not incur the original R&D expenses.
• Patent Expiry: The legal expiration of exclusive rights, allowing other companies to manufacture and sell generic versions of a drug.
• Off-label use: Using a medication for a purpose other than what it was officially approved for (e.g., cosmetic weight loss).

---

1. The Market Shift in India

India has experienced a significant surge in the availability and affordability of weight-loss drugs following the expiration of the patent for semaglutide earlier this year.

• Price Reduction: Costs have plummeted from $150–$175 per month to $15–$20 per month.
• Market Growth: Within the first month of generic availability, prescription rates increased by approximately seven times.
• Industry Response: Roughly 30 to 40 generic versions of the drug have entered the Indian market, significantly increasing accessibility for the population.

2. Drivers of Demand

The boom in demand for these drugs in India is attributed to several converging factors:

• Health Crisis: India is often referred to as the "diabetes capital of the world," with approximately 100 million diabetics. Obesity and diabetes are closely linked, and one in four Indians is now classified as overweight.
• Lifestyle Changes: Increased affluence and sedentary lifestyles have contributed to rising obesity rates.
• Middle-Class Awareness: A growing middle class with higher disposable income is increasingly focused on health and aesthetic appearance, seeking "quick solutions."

3. Mechanism of Action

Health correspondent James Gallagher explains the biological function of GLP-1 receptor agonists:

• Natural Process: When eating, the body naturally releases GLP-1, which travels to the brain to signal fullness.
• Drug Intervention: Synthetic versions (semaglutide) are engineered to resist the body’s natural breakdown process. By remaining in the system longer, they provide a constant signal to the brain that the body is full, thereby suppressing appetite.
• Side Effects: Common side effects include nausea and digestive issues (constipation or gastrointestinal distress).
• Rebound Effect: If the medication is discontinued, the appetite-suppressing signal ceases, often leading to rapid weight regain as the body attempts to compensate for previous caloric restriction.

4. Regulatory and Ethical Challenges

The rapid influx of these drugs has created regulatory hurdles:

• Illegal Distribution: Previously, some gyms, beauty clinics, and online pharmacies were dispensing these drugs without prescriptions.
• Government Crackdown: Authorities have tightened regulations, conducting raids on clinics and issuing strict advisories to pharmaceutical companies to prevent irresponsible advertising and ensure the drugs are only sold via valid medical prescriptions.
• Medical Perspective: Dr. Kiran, a medical practitioner, emphasizes that while these drugs are a "game changer" for patients with obesity, social media-driven fear regarding rare side effects often prevents those who genuinely need the treatment from seeking it.

5. Global Implications

As the "pharmacy of the world," India’s production of generic GLP-1s is expected to have a global impact:

• Addressing Shortages: Indian manufacturers are already negotiating contracts to export generic versions to Canada, the Middle East, and Africa.
• Global Price Pressure: As patents expire in other regions, the entry of Indian generics is expected to lower global prices and help alleviate supply shortages.

Synthesis

The transition of weight-loss drugs from high-cost, patented products to affordable generics in India represents a major public health development. While it offers a vital tool for managing obesity and diabetes, it necessitates stringent regulatory oversight to prevent misuse for cosmetic purposes. As India scales its production, it is positioned to play a pivotal role in democratizing access to these treatments on a global scale.